Table 1. Justifications for the final CONITEC recommendations found in the health technology exclusion reports, from 2012 to 2023.

Justifications for exclusion	Number of technologies (n = 70)	Percentage of technologies (%)
PCDTa changes	13	18.57
ANVISAb registration expired, cancelled or inexistentb	22	31.43
Production discontinuation	3	4.28
Existence of available therapeutic alternatives with better therapeutic efficacy and safety profile	20	28.57
Clinical evidence of insufficient efficacy	14	20
Prohibition of commercialization, distribution, manufacture, import, manipulation and advertising	3	4.29
Exclusion of the technology with which its use was associated	2	2.86
Disuse of technology in the CEAFc	14	20

a) Clinical Protocols and Treatment Guidelines; b) National Health Surveillance Agency; c) Specialized Component of Pharmaceutical Care.

Note: Multiple reasons for exclusion were identified for the same technology. The proportion in the third column refers to the total number of individual assessments that with final recommendation for exclusion from the SUS (n = 70).